GW PHARMACEUTICALS PLC
GW PHARMACEUTICALS PLC (GWPH): 5 pipeline candidates · ~137 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
137.3 months
D/E 0.27 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for GW PHARMACEUTICALS PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$458.1M
Quarterly Burn
$11.7M
Runway
137.3 mo
Revenue
$152.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| epidiolex | Phase 3 |
| gwp42003 | Phase 2 |
| gwp42006 | Phase 2 |
| intravenous gwp42003 | Phase 2 |
| nabiximols | Phase 3 |
Frequently asked questions
How many drug candidates are in GW PHARMACEUTICALS PLC's pipeline?
GW PHARMACEUTICALS PLC (GWPH) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GW PHARMACEUTICALS PLC's lead drug candidate?
GW PHARMACEUTICALS PLC's most advanced tracked candidate is epidiolex (Phase 3) for Rett syndrome.
What is GW PHARMACEUTICALS PLC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GW PHARMACEUTICALS PLC has approximately 137.3 months of cash runway.
Who is the CEO of GW PHARMACEUTICALS PLC?
San Francisco is the chief executive officer of GW PHARMACEUTICALS PLC (GWPH).
Get the full picture on GW PHARMACEUTICALS PLC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.